TY - JOUR
T1 - Erratum
T2 - Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor (Cancer Cell (2014) 26(6) (909–922) (S1535610814004231) (10.1016/j.ccell.2014.10.019))
AU - Christensen, Camilla L.
AU - Kwiatkowski, Nicholas
AU - Abraham, Brian J.
AU - Carretero, Julian
AU - Al-Shahrour, Fatima
AU - Zhang, Tinghu
AU - Chipumuro, Edmond
AU - Herter-Sprie, Grit S.
AU - Akbay, Esra A.
AU - Altabef, Abigail
AU - Zhang, Jianming
AU - Shimamura, Takeshi
AU - Capelletti, Marzia
AU - Reibel, Jakob B.
AU - Cavanaugh, Jillian D.
AU - Gao, Peng
AU - Liu, Yan
AU - Michaelsen, Signe R.
AU - Poulsen, Hans S.
AU - Aref, Amir R.
AU - Barbie, David A.
AU - Bradner, James E.
AU - George, Rani E.
AU - Gray, Nathanael S.
AU - Young, Richard A.
AU - Wong, Kwok Kin
N1 - Publisher Copyright:
© 2015 Elsevier Inc.
PY - 2015/1/12
Y1 - 2015/1/12
N2 - (Cancer Cell 26, 909–922; December 8, 2014) Following publication of the manuscript, the authors identified an inadvertent error in the text associated with Figure 6D in the Results. Although NFIB is associated with a super-enhancer, it was not part of the leading-edge gene set from the enrichment analysis (Figures 6A and 6C). NFIB is not listed in Figure 6C, which displays the final filtered transcription factor gene list. Thus, Figure 6C is correct and the error was confined to the text. In addition, we inadvertently left out the full acknowledgment for a major funding institution for this project: the Bridge Project. Thus, the previous acknowledgment text has been replaced with the following: “This work was also supported by the Bridge Project (K.-K.W., N.S.G., and R.A.Y.), a collaboration between The Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center (DF/HCC).” The online text has been corrected to reflect the above changes.
AB - (Cancer Cell 26, 909–922; December 8, 2014) Following publication of the manuscript, the authors identified an inadvertent error in the text associated with Figure 6D in the Results. Although NFIB is associated with a super-enhancer, it was not part of the leading-edge gene set from the enrichment analysis (Figures 6A and 6C). NFIB is not listed in Figure 6C, which displays the final filtered transcription factor gene list. Thus, Figure 6C is correct and the error was confined to the text. In addition, we inadvertently left out the full acknowledgment for a major funding institution for this project: the Bridge Project. Thus, the previous acknowledgment text has been replaced with the following: “This work was also supported by the Bridge Project (K.-K.W., N.S.G., and R.A.Y.), a collaboration between The Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center (DF/HCC).” The online text has been corrected to reflect the above changes.
UR - http://www.scopus.com/inward/record.url?scp=85040535738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040535738&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2014.12.007
DO - 10.1016/j.ccell.2014.12.007
M3 - Comment/debate
AN - SCOPUS:85040535738
SN - 1535-6108
VL - 27
SP - 149
JO - Cancer Cell
JF - Cancer Cell
IS - 1
ER -